Saudi Central Bank Has $2.93 Million Holdings in IDEXX Laboratories, Inc. $IDXX

Saudi Central Bank raised its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 88.7% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,560 shares of the company’s stock after acquiring an additional 2,613 shares during the period. Saudi Central Bank’s holdings in IDEXX Laboratories were worth $2,927,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in IDXX. Elyxium Wealth LLC acquired a new stake in IDEXX Laboratories in the fourth quarter valued at approximately $3,666,459,000. J. Stern & Co. LLP increased its holdings in shares of IDEXX Laboratories by 23,694.7% during the fourth quarter. J. Stern & Co. LLP now owns 2,653,351 shares of the company’s stock worth $1,795,072,000 after buying an additional 2,642,200 shares in the last quarter. Northwestern Mutual Wealth Management Co. increased its holdings in shares of IDEXX Laboratories by 63,503.9% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 1,444,445 shares of the company’s stock worth $977,210,000 after buying an additional 1,442,174 shares in the last quarter. Bank of New York Mellon Corp bought a new position in shares of IDEXX Laboratories in the 2nd quarter valued at $628,223,000. Finally, Wellington Management Group LLP boosted its holdings in shares of IDEXX Laboratories by 318.1% during the 4th quarter. Wellington Management Group LLP now owns 779,214 shares of the company’s stock valued at $527,162,000 after acquiring an additional 592,834 shares in the last quarter. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Performance

Shares of IDXX stock opened at $535.38 on Tuesday. IDEXX Laboratories, Inc. has a 1-year low of $518.55 and a 1-year high of $769.98. The company has a current ratio of 1.17, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19. The stock has a market cap of $42.18 billion, a price-to-earnings ratio of 37.65, a PEG ratio of 2.86 and a beta of 1.54. The stock has a 50-day moving average of $558.25 and a 200-day moving average of $569.41.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Tuesday, August 4th. The company reported $4.27 EPS for the quarter, beating the consensus estimate of $3.94 by $0.33. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%.The business had revenue of $1.22 billion for the quarter, compared to analysts’ expectations of $1.20 billion. During the same period in the prior year, the business posted $3.50 earnings per share. The firm’s revenue was up 9.7% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. On average, equities research analysts forecast that IDEXX Laboratories, Inc. will post 14.81 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on IDXX shares. Weiss Ratings lowered IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday, August 27th. Wall Street Zen lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Barclays reduced their price target on IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating on the stock in a report on Tuesday, August 11th. Citigroup upped their price objective on IDEXX Laboratories from $650.00 to $670.00 and gave the company a “neutral” rating in a research note on Wednesday, August 5th. Finally, UBS Group lifted their target price on shares of IDEXX Laboratories from $620.00 to $670.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 5th. Six equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and an average target price of $747.00.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.